Showing results (91-100 of 130) with videos related to
Sort By:
Pageof 13
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2011
Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studiesTimothy A Yap, David Olmos, Andre T Brunetto, et al.The New England Journal of Medicine|February 9, 2018
Apalutamide Treatment and Metastasis-free Survival in Prostate CancerMatthew R Smith, Fred Saad, Simon Chowdhury, et al.Translational Research : the Journal of Laboratory and Clinical Medicine|September 11, 2022
Tumor suppressor role of RBM22 in prostate cancer acting as a dual-factor regulating alternative splicing and transcription of key oncogenic genesJuan M Jiménez-Vacas, Antonio J Montero-Hidalgo, Enrique Gómez-Gómez, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2022
Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNANobuaki Matsubara, Johann de Bono, David Olmos, et al.European Urology Oncology|May 6, 2025
Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE TrialKim N Chi, Elena Castro, Gert Attard, et al.European Urology Oncology|July 17, 2019
Risk Prediction Tools Available for Germline BRCA1/2 Mutations Underperform in Prostate Cancer PatientsLucía Oliva, Rebeca Lozano, Casilda Llácer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 14, 2023
Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in <i>BRCA1</i> and/or <i>BRCA2</i> in the PROfound TrialJoaquin Mateo, Johann S de Bono, Karim Fizazi, et al.Journal of Managed Care & Specialty Pharmacy|July 5, 2023
Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defectsMatthew R Smith, Shahneen Sandhu, Daniel J George, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 23, 2012
Patient selection for oncology phase I trials: a multi-institutional study of prognostic factorsDavid Olmos, Roger P A'hern, Silvia Marsoni, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2023
Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate CancerKim N Chi, Dana Rathkopf, Matthew R Smith, et al.Pageof 13